Unknown

Dataset Information

0

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.


ABSTRACT:

Background

We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.

Methods

The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.

Results

Cross-sectional evaluation of the first 151 participants (age 64?±?8, 44% female, Mini-Mental State Examination 29?±?2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n?=?114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age???60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.

Conclusions

The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

SUBMITTER: Slot RER 

PROVIDER: S-EPMC6080529 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.<h4>Methods</h4>The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure  ...[more]

Similar Datasets

| S-EPMC7034269 | biostudies-literature
| S-EPMC7392684 | biostudies-literature
2015-08-05 | E-GEOD-63063 | biostudies-arrayexpress
| S-EPMC6993088 | biostudies-literature
2015-08-05 | E-GEOD-63061 | biostudies-arrayexpress
| S-EPMC4122459 | biostudies-other
| S-EPMC5765251 | biostudies-literature
| S-EPMC7606422 | biostudies-literature
2015-08-05 | GSE63063 | GEO
| S-EPMC6249104 | biostudies-literature